Attached files
| file | filename |
|---|---|
| 8-K - PHARMACYCLICS INC | form8k07380a_11072013.htm |
| EX-99.9 - PHARMACYCLICS INC | ex999to8k07380a_11072013.htm |
| EX-99.8 - PHARMACYCLICS INC | ex998to8k07380a_11072013.htm |
| EX-99.5 - PHARMACYCLICS INC | ex995to8k07380a_11072013.htm |
| EX-99.6 - PHARMACYCLICS INC | ex996to8k07380a_11072013.htm |
| EX-99.3 - PHARMACYCLICS INC | ex993to8k07380a_11072013.htm |
| EX-99.4 - PHARMACYCLICS INC | ex994to8k07380a_11072013.htm |
| EX-99.2 - PHARMACYCLICS INC | ex992to8k07380a_11072013.htm |
| EX-99.7 - PHARMACYCLICS INC | ex997to8k07380a_11072013.htm |
| EX-99.12 - PHARMACYCLICS INC | ex9912to8k07380a_11072013.htm |
| EX-99.17 - PHARMACYCLICS INC | ex9917to8k07380a_11072013.htm |
| EX-99.18 - PHARMACYCLICS INC | ex9918to8k07380a_11072013.htm |
| EX-99.16 - PHARMACYCLICS INC | ex9916to8k07380a_11072013.htm |
| EX-99.13 - PHARMACYCLICS INC | ex9913to8k07380a_11072013.htm |
| EX-99.20 - PHARMACYCLICS INC | ex9920to8k07380a_11072013.htm |
| EX-99.15 - PHARMACYCLICS INC | ex9915to8k07380a_11072013.htm |
| EX-99.10 - PHARMACYCLICS INC | ex9910to8k07380a_11072013.htm |
| EX-99.11 - PHARMACYCLICS INC | ex9911to8k07380a_11072013.htm |
| EX-99.14 - PHARMACYCLICS INC | ex9914to8k07380a_11072013.htm |
| EX-99.21 - PHARMACYCLICS INC | ex9921to8k07380a_11072013.htm |
| EX-99.19 - PHARMACYCLICS INC | ex9919to8k07380a_11072013.htm |
| EX-99.22 - PHARMACYCLICS INC | ex9922to8k07380a_11072013.htm |
Exhibit 99.1
American Society of Hematology (ASH) Annual Meeting: New Orleans, LA; Dec. 7 – 10
|
Title
|
Presenting Author
|
Status
|
Presentation Date/time
|
|||
|
The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-term Safety and Durability of Response in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in an Open-Label Extension Study
|
Dr. O’Brien
|
Poster
|
Session Name: 642. CLL: Therapy, excluding Transplantation: Poster III
Date: Monday, December 9, 2013
Presentation Time: 6:00 PM - 8:00 PM
Location: Ernest N. Morial Convention Center, Hall E
|
|||
|
Ibrutinib in Combination with Bendamustine and Rituximab is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase 1b Study
|
Dr. Brown
|
Oral
|
Session Name: 642. CLL: Therapy, excluding Transplantation: Chemoimmunotherapy Clinical Trials Session Date: Monday, December 9, 2013 Session Time: 2:45 PM - 4:15 PM Presentation Time: 3:15 PM
Room: Ernest N. Morial Convention Center, 220-222
|
|||
|
Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study in Patients With CD20-Positive B-Cell non-Hodgkin’s lymphoma
|
Dr. Younes
|
Oral
|
Session Name: 624. Lymphoma: Therapy with Biological Agents, Excluding Pre-Clinical Models: Aggressive Lymphomas
Session Date: Tuesday, December 10, 2013
Session Time: 7:30 AM - 9:00 AM
Presentation Time: 8:45 AM Room: Ernest N. Morial Convention Center, La Nouvelle Ballroom AB
|
|||
|
A Prospective Multicenter Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib in Patients with Relapsed or Refractory Waldenstrom’s Macroglobulinemia
|
Dr. Treon
|
Oral
|
Session Name: 624.Lymphoma: Therapy with Biological Agents, Excluding Pre-Clinical Models: Novel Therapies for Indolent Lymphomas
Session Date: Monday, December 9, 2013
Session Time: 7:00 AM - 8:30 AM
Presentation Time: 8:00 AM
Room: Ernest N. Morial Convention Center, La Nouvelle Ballroom AB
|
|||
|
Somatic activating mutations in CXCR4 are common in patients with Waldenstrom’s Macrogloblinemia, and their expression in WM cells promotes resistance to ibrutinib
|
Dr. Cao
|
Poster
|
Session Name: 625. Lymphoma: Pre-Clinical- Chemotherapy and Biologic Agents: Poster III
Date: Monday, December 9, 2013
Presentation Time: 6:00 PM-8:00 PM
Location: ENM Convention Center, Hall G
|
|||
|
Changing the Treatment Paradigm for Previously Treated Chronic Lymphocytic Leukemia Patients with Del(17p) Karyotype
|
Dr. Stephens
|
Poster
|
Session Name: 642. Therapy, excluding Transplantation: Poster II
Date: Sunday, December 8, 2013
Presentation Time: 6:30 PM – 8:30 PM
Location: Hall E ENM Convention Center
|
|||
|
Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk Chronic Lymphocytic Leukemia (CLL): new, updated results of a Phase II trial in 40 patients
|
Dr. Burger
|
Oral
|
Session Name: 642. CLL: Therapy, excluding Transplantation: Clinical Trials of B Cell Receptor Signaling Inhibitors
Session Date: Monday, December 9, 2013
Session Time: 4:30 PM - 6:00 PM
Presentation Time: 5:00 PM
Room: Ernest N. Morial Convention Center, 295-296
|
|||
|
Kinetics of chronic lymphocytic leukemia cells in tissues and blood during therapy with the BTK inhibitor ibrutinib
|
Dr. Wodarz
|
Poster
|
Session Name: 642. CLL: Therapy, excluding Transplantation: Poster III session
Date: Monday, December 9, 2013
Presentation Time: 6:00 PM - 8:00 PM
Location: Ernest N. Morial Convention Center, Hall E
|
|||
|
Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Interferes with Constitutive and Induced Pre-B Cell Receptor Signaling in B-cell Acute Lymphoblastic Leukemia
|
Dr. Kim
|
Poster
|
Session Name: 612. Acute Lymphoblastic Leukemia: Pathophysiology & Clinical Studies: Poster I
Date: Saturday, December 7, 2013
Presentation Time: 5:30 PM - 7:30 PM
Location: Ernest N. Morial Convention Center, Hall E
|
|
Ibrutinib differentially interferes with surface IgM and IgD BCR signaling activation kinetics in Chronic Lymphocytic Leukemia
|
Dr. ten Hacken
|
Poster
|
Session Name: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III
Date: Monday, December 9, 2013
Presentation Time: 6:00 PM - 8:00 PM
Location: Ernest N. Morial Convention Center, Hall E
|
|||
|
Longitudinal Gene Expression Profiling Reveals Down-regulation of BCR Signaling-related Genes in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Ibrutinib plus Rituximab
|
Dr. Hoellenriegel
|
Poster
|
Session Name: 642. CLL: Therapy, excluding Transplantation: Poster I
Date: Saturday, December 7, 2013
Presentation Time: 5:30 PM - 7:30 PM
Location: Ernest N. Morial Convention Center, Hall E
|
|||
|
Clonal evolution in patients with chronic lymphocytic leukemia developing resistance to BTK inhibition
|
Dr. Burger
|
Oral
|
Session Name: 641. CLL: Biology and Pathophysiology, excluding Therapy: Molecular Mechanisms of CLL and Genomic Alterations in CLL Pathogenesis
Session Date: Tuesday, December 10, 2013
Session Time: 7:30 AM - 9:00 AM
Presentation Time: 7:45 AM
Room: Ernest N. Morial Convention Center, 288-290
|
|||
|
Single agent Ibrutinib (PCI-32765) achieves equally good and durable responses in chronic lymphocytic leukemia (CLL) patients with and without deletion 17p
|
Dr. Farooqui
|
Oral
|
Session Name: 642. CLL: Therapy, excluding Transplantation: Clinical Trials of B Cell Receptor Signaling Inhibitors
Session Date: Monday, December 9, 2013
Session Time: 4:30 PM - 6:00 PM
Presentation Time: 4:30 PM
Room: Ernest N. Morial Convention Center, 295-296
|
|||
|
Ibrutinib inhibits B-cell adhesion and causes an efflux of chronic lymphocytic leukemia cells from the tissue microenvironment into the blood leading to a transient treatment-induced lymphocytosis
|
Dr. Mustafa
|
Oral
|
Session Name: 642. CLL: Therapy, excluding Transplantation
Session Date: Monday, December 9, 2013
Session Time: 4:30 PM – 6:00 PM
Presentation Time: 4:45 PM
Room: Ernest N. Morial Convention Center, 295-296
|
|||
|
In patients with chronic lymphocytic leukemia (CLL) ibrutinib effectively reduces clonal IgM paraproteins and serum free light chains while increasing normal IgM, IgA serum levels, suggesting a nascent recovery of humoral immunity
|
Dr. Aue
|
Poster
|
Session Name: 642. CLL: Therapy, excluding Transplantation: Poster III
Session Date: Monday, December 9, 2013
Session Time: 6:00 PM - 8:00 PM
Room: Ernest N. Morial Convention Center, Hall E
|
|||
|
Cytokine and T cell phenotypic changes upon in vivo ibrutinib therapy for CLL – targeting both CLL and the tumor-microenvironment
|
Dr. Niemann
|
Poster
|
Session Name: 641. CLL: Biology and Pathophysiology
Session Date: Sunday, December 8, 2013
Session Time: 6:30 PM - 8:30 PM
Room: Hall E
|
|||
|
Effective inhibition of tumor microenvironment interactions in CLL patients treated with the BTK inhibitor ibrutinib result in sustained inhibition of tumor proliferation and survival pathways
|
Dr. Herman
|
Oral
|
Session Name: 641. CLL: Biology and Pathophysiology
Session Date: Sunday, December 8, 2013
Session Time: 5:00 PM – 6:30 PM
Presentation Time: 5:45 PM
Room: Ernest N. Morial Convention Center, 288-290
|
|||
|
In-vivo effects of ibrutinib on the migration of chronic lymphocytic leukemia cells differ between patients and reduce the ability of the bone marrow microenvironment to attract the tumor cells
|
Dr. Herman
|
Oral
|
Session Name: 604. Molecular Pharmacology, Drug Resistance
Session Date: Monday, December 9, 2013
Session Time: 4:30 PM – 6:00 PM
Presentation Time: 5:15 PM
Room: Ernest N. Morial Convention Center, 275-277
|
|||
|
Possible mechanisms of resistance to the novel BH3-mimetic ABT-199 in in vitro lymph node models of CLL – the role of Abl and Btk
|
Dr. Thijssen
|
Poster
|
Session Name: 642. CLL: Therapy, excluding Transplantation: Poster III
Date: Monday, December 9, 2013
Presentation Time: 6:00 PM - 8:00 PM
Location: Ernest N. Morial Convention Center, Hall E
|
|||
|
Rituximab But Not GA101 Is Partially Antagonistic With Inhibitors Of The B-Cell Receptor Pathway In Diffuse Large B-Cell Lymphoma
|
Dr. Zoellner
|
Poster
|
Session Name: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster III
Date: Monday, December 9, 2013: , 6:00 PM-8:00 PM
Location: Ernest N. Morial Convention Center, Hall G
|
|||
|
Ibrutinib (PCI-32765) antagonizes Rituximab-dependent NK-cell mediated cytotoxicity
|
Dr. Kohrt
|
Oral
|
Session Name: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Modulating the Immune System in Lymphoma
Session Date: Monday, December 9, 2013
Session Time: 10:30 AM - 12:00 PM
Presentation Time: 10:30 AM
Room: Ernest N. Morial Convention Center, 220-222
|